| Routes Of Administration: | Unspecified |
| Class: | Trace amine-associated receptor 1 (TAAR1) agonist |
| Synonyms: | RG7410 |
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.[1] [2] Its route of administration was unspecified.
The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was under development by Hoffmann-La Roche. RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.[4]